---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: IL-17 inhibitors"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: IL-17 inhibitors. Topics: Biologics guideline: recommendations for secukinumab, ixekizumab, and brodalumab, and inflammatory bowel disease; Secukinumab: FDA-approved indication, dosage, and week 12 outcomes in Trials PsO1 and PsO2; Ixekizumab: FDA-approved indication, dosage, and week 12 outcomes in Trial 1; Brodalumab: boxed warning for suicidal ideation and behavior, REMS, restricted indication, and dosage; 6 further topics. 10 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/il-17-inhibitors"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: IL-17 inhibitors

<a id="heading-2.2.2.1.9"></a>

## 2.2.2.1.9 IL-17 Inhibitors

<a id="topic-2.2.2.1.9-1"></a>

### Biologics guideline: recommendations for secukinumab, ixekizumab, and brodalumab, and inflammatory bowel disease

> “Secukinumab is recommended as a monotherapy treatment option in adult patients with moderate-to-severe plaque psoriasis”
> “Secukinumab is recommended at a dose of 300 mg, which is more effective than 150 mg”
> “Ixekizumab is recommended as a monotherapy treatment option for use in adult patients with moderate-to-severe plaque psoriasis”
> “Brodalumab is recommended as a monotherapy treatment option in adult patients with moderate-to-severe plaque psoriasis”
> “Although the number of patients presenting with this adverse effect in clinical trials was relatively small, it is recommended that the use of IL-17 inhibitors be avoided in patients with a personal history of or active IBD.”
> “Periodic assessment of suicidal ideation is recommended for patients treated with brodalumab and might necessitate more frequent follow-up visits”

Source: [Menter et al. (2019)](https://www.jaad.org/article/S0190-9622%2818%2933001-9/fulltext)

<a id="topic-2.2.2.1.9-2"></a>

### Secukinumab: FDA-approved indication, dosage, and week 12 outcomes in Trials PsO1 and PsO2

> “COSENTYX® is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy.”
> “The recommended dosage in adults with moderate to severe PsO is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.”
> “PASI 90 response at Week 12 was achieved with COSENTYX 300 mg and 150 mg compared to placebo in 59% (145/245) and 39% (95/245) versus 1% (3/248) of subjects, respectively (Trial PsO1) and 54% (175/327) and 42% (137/327) versus 2% (5/326) of subjects, respectively (Trial PsO2).”

Source: [Novartis COSENTYX prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125504s101;761349s016lbl.pdf)

| Outcome at Week 12, Trial PsO1, n (%) | COSENTYX 300 mg (N = 245) | COSENTYX 150 mg (N = 245) | Placebo (N = 248) |
| --- | --- | --- | --- |
| PASI 75 response | “200 (82)” | “174 (71)” | “11 (4)” |
| IGA of clear or almost clear | “160 (65)” | “125 (51)” | “6 (2)” |

Source: [Novartis COSENTYX prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125504s101;761349s016lbl.pdf)

<a id="topic-2.2.2.1.9-3"></a>

### Ixekizumab: FDA-approved indication, dosage, and week 12 outcomes in Trial 1

> “TALTZ® is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.”
> “The recommended dosage in adults with moderate-to-severe plaque psoriasis is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.”

Source: [Eli Lilly TALTZ prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125521s032lbl.pdf)

| Outcome at Week 12, Trial 1, n (%) | TALTZ 80 mg Q2W (N=433) | Placebo (N=431) |
| --- | --- | --- |
| sPGA of 0 (clear) or 1 (minimal) | “354 (82)” | “14 (3)” |
| PASI 90 | “307 (71)” | “2 (1)” |
| PASI 100 | “153 (35)” | “0” |

Source: [Eli Lilly TALTZ prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125521s032lbl.pdf)

<a id="topic-2.2.2.1.9-4"></a>

### Brodalumab: boxed warning for suicidal ideation and behavior, REMS, restricted indication, and dosage

> “Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ.”
> “Because of the observed suicidal behavior in subjects treated with SILIQ, SILIQ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SILIQ REMS Program [see Warnings and Precautions (5.2)].”
> “SILIQ® (brodalumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.”
> “The recommended SILIQ dose is 210 mg administered by subcutaneous injection at Weeks 0, 1, and 2 followed by 210 mg every 2 weeks.”
> “If an adequate response has not been achieved after 12 to 16 weeks of treatment with SILIQ, consider discontinuing therapy.”

Source: [Bausch Health SILIQ prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761032s020lbl.pdf)

<a id="topic-2.2.2.1.9-5"></a>

### Brodalumab versus ustekinumab and placebo: week 12 outcomes in Trial 2

| Outcome at Week 12, Trial 2, n (%) | SILIQ 210 mg Q2W (N=612) | Ustekinumab (N=300) | Placebo (N=309) |
| --- | --- | --- | --- |
| PASI 75 response | “528 (86)” | “210 (70)” | “25 (8)” |
| PASI 100 response | “272 (44)” | “65 (22)” | “2 (1)” |

Source: [Bausch Health SILIQ prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761032s020lbl.pdf)

<a id="topic-2.2.2.1.9-6"></a>

### Bimekizumab: FDA-approved indication, dosage, suicidal ideation warning, and week 16 outcomes

> “BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.”
> “The recommended dosage is 320 mg by subcutaneous injection at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter.”
> “For patients weighing 120 kg or more, consider a dosage of 320 mg every 4 weeks after Week 16 [see Clinical Pharmacology (12.3)].”
> “An increased incidence of new onset or worsening suicidal ideation and behavior was observed in subjects treated with BIMZELX.”

Source: [UCB BIMZELX prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761151s010lbl.pdf)

| Outcome at Week 16, n (%) | Trial Ps-1 BIMZELX 320 mg every 4 weeks (N=321) | Trial Ps-1 placebo (N=83) | Trial Ps-2 BIMZELX 320 mg every 4 weeks (N=349) | Trial Ps-2 placebo (N=86) |
| --- | --- | --- | --- | --- |
| IGA 0 or 1 | “270 (84%)” | “4 (5%)” | “323 (93%)” | “1 (1%)” |
| PASI 90 | “273 (85%)” | “4 (5%)” | “317 (91%)” | “1 (1%)” |
| PASI 100 | “188 (59%)” | “0 (0%)” | “238 (68%)” | “1 (1%)” |

Source: [UCB BIMZELX prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761151s010lbl.pdf)

<a id="topic-2.2.2.1.9-7"></a>

### BE RADIANT: bimekizumab versus secukinumab, PASI 100 at weeks 16 and 48 and oral candidiasis

> “A total of 1005 patients were screened and 743 were enrolled; 373 patients were assigned to receive bimekizumab and 370 to receive secukinumab.”
> “At week 16, a total of 230 patients (61.7%) in the bimekizumab group and 181 (48.9%) in the secukinumab group had a 100% reduction from baseline in the PASI score (PASI 100) (adjusted risk difference, 12.7 percentage points; 95% confidence interval [CI], 5.8 to 19.6); bimekizumab was shown to be noninferior and superior to secukinumab (P<0.001 for noninferiority and superiority).”
> “At week 48, a total of 250 patients (67.0%) treated with bimekizumab had a PASI 100 response, as compared with 171 patients (46.2%) treated with secukinumab (adjusted risk difference, 20.9 percentage points; 95% CI, 14.1 to 27.7; P<0.001).”
> “Oral candidiasis occurred more often with bimekizumab (72 patients, 19.3%) than with secukinumab (11 patients, 3.0%).”
> “(Funded by UCB Pharma; BE RADIANT ClinicalTrials.gov number, NCT03536884.)”

Source: [Reich et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33891380/)

<a id="topic-2.2.2.1.9-8"></a>

### Guideline statements: bimekizumab safety profile and candidiasis

> “In the opinion of the guideline group, bimekizumab has, with the exception of candidiasis, a similar safety profile to other IL‐17 antagonists, such as ixekizumab and secukinumab, as well as the IL‐17R antagonist brodalumab.”
> “Infections: The three most common TEAEs were nasopharyngitis (19.1 per 100 person‐years; 95% CI 17.4–20.9 per 100 person‐years), oral candidiasis (12.6 per 100 person‐years; 95% CI 11.3–14.0 per 100 person‐years), and infections of the upper respiratory tract (8.9 per 100 person‐years; 95% CI 7.8–10.1 per 100 person‐years).”
> “Dual inhibition of IL‐17A and IL‐17F may impair the protective function of mucous membranes more strongly, thus increasing the risk of oral candidiasis.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.1.9-9"></a>

### Decision aid: IL-17 inhibitors

| Agent | Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months? | What is the likelihood of staying on this treatment for more than 1 year? |
| --- | --- | --- |
| Bimekizumab | “54%” | “Not known at present” |
| Brodalumab | “50%” | “Not known at present” |
| Ixekizumab | “53%” | “77–83% chance” |
| Secukinumab | “47%” | “80–83% chance” |

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

<a id="topic-2.2.2.1.9-10"></a>

### Network meta-analysis: anti-IL-17 agents compared with placebo and with other classes

> “In terms of reaching PASI 90, anti‐IL17 treatments (secukinumab, ixekizumab, izokibep, brodalumab, bimekizumab, sonelokimab, and xeligekimab) were more effective than placebo (class‐level RR 27.19, 95% CI 19.49 to 37.92).”
> “At class level, anti‐IL17 treatment showed a higher proportion of participants reaching PASI 90 compared to all the interventions versus anti‐IL23 (RR 1.15, 95% CI 1.01 to 1.31); versus anti‐IL12/23 (RR 1.44, 95% CI 1.27 to 1.64); versus anti‐TNF‐alpha (RR 1.92, 95% CI 1.68 to 2.19); versus TYK‐2 inhibitors (RR 3.20, 95% CI 2.08 to 4.94); versus non‐targeted systemic treatments (RR 4.01, 95% CI 2.65 to 6.05); and versus phosphodiesterase‐4 inhibitors (RR 5.82, 95% CI 3.95 to 8.58) (Supplementary material 15).”
> “There was evidence of a difference in favour of bimekizumab, ixekizumab, and risankizumab compared to secukinumab in terms of achieving PASI 90.”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

| Treatment | PASI 75 at 10 to 16 weeks, % (95% CrI) | PASI 90 at 10 to 16 weeks, % (95% CrI) | PASI 100 at 10 to 16 weeks, % (95% CrI) |
| --- | --- | --- | --- |
| Ixekizumab, 80 mg | “88.8 (86.5-90.9)” | “70.8 (66.8-74.6)” | “39.5 (35.2-44.0)” |
| Brodalumab, 210 mg | “88.7 (86.5-90.8)” | “70.6 (66.8-74.6)” | “39.2 (35.2-43.9)” |
| Secukinumab, 300 mg | “83.1 (80.2-85.7)” | “61.4 (57.2-65.6)” | “29.9 (26.3-33.9)” |

Source: [Armstrong et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
